Press Releases Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:10:19 2026-01-13 pm EST			5-day change	1st Jan Change
0.4020 ^USD	-2.47%		+1.44%	-2.32%

07:55am	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI

Press Releases

07:48am	Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities	PR
Dec. 18	Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial	PU
Dec. 18	Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations	PU
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium	PR
Dec. 08	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	AQ
Dec. 05	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	PR
Nov. 06	Intensity Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
25-10-31	Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock	PR
25-09-02	Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	PR
25-08-12	Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	PR
25-08-07	Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	PR
25-08-04	Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025	PR
25-06-30	Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)	PR
25-06-11	Intensity Therapeutics, Inc. Announces Pricing of Public Offering	PR
25-06-11	Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock	PR
25-06-11	Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study	PR
25-06-01	Hypothesis: In a randomized controlled study, Intratumoral INT230-6 dosed alone into a few large tumors will increase overall survival for patients with metastatic sarcomas compared to the best systemic, standard-of-care therapies	PU
25-05-13	Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update	PR
25-05-06	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France	PR
25-04-25	Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering	PR
25-03-13	Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update	PR
25-01-29	Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics Ongoing Global Randomized Phase 3 Sarcoma Trial Following Periodic Review	AQ
25-01-28	Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review	PR
25-01-10	Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6	PR
24-12-12	Evaluation of Pathological Complete Response (pCR) and Immunomodulatory Effects Following Intratumoral Injection of INT230 6 Prior to Neoadjuvant Immuno chemotherapy in Early Stage Triple Negative Breast Cancer (TNBC): A Phase II Randomized Study, the INVINCIBLE 4 SAKK 66/22 Trial. NCT06358573	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Press Releases

Filters